BIFIDOBACTERIUM LACTIS Bl-04®
Learn more about our premium strain for immune health
AIM OF THE STUDY
This study was designed to understand if daily intake of a formulation containing Bifidobacterium lactis Bl-04® would have a positive impact in the prevention of upper respiratory tract (URT) illness episodes
PRODUCT FORMULA
Bifidobacterium lactis Bl-04® 2 Billion CFU
STUDY DESIGN
5 month, double-blind, placebo-controlled study
Evaluation of symptoms & physical activity via Web-based questionnaire.
SUBJECTS
310 healthy physically active-adults, average age of 35 years
UNIVERSITY
Griffith Health Institute, Griffith University & Australian Institute of sport, Australia
PUBLICATION
West et al. 2014 Clinical Nutrition
AIM OF THE STUDY
To study the effect of Bifidobacterium lactis Bl-04® on immune response and rhinovirus load during rhinovirus infection that causes common cold.
PRODUCT FORMULA
Bifidobacterium lactis Bl-04® 2 Billion CFU
STUDY DESIGN
Randomized, double-blind, placebo controlled study.
SUBJECTS
115 healthy adults
OUTCOMES
Nasal immune response (IL-8), nasal rhinovirus load
UNIVERSITY
University of Virginia, USA; Prof. Ronald B Turner
PUBLICATION
Turner et al. Beneficial Microbes 2017
Strong clinical evidence from community-based study
- Results showed a significant decrease of 27% in the percentage of URTI episodes in the Bl-04® group vs placebo group (Kang et al., 2013)
- 0.7 month delay of median time for first respiratory infections compared to the plcebo group
- Robust long term study completed with a high number of subjects. (310 subjects / 5 months)
Unique evidence from the rhinovirus challenge study
- In the Bl-04® group, less virus was detected in the nasal washes compared to placebo during the infection
- Decreased proportion of subjects who had a detectable amount of virus
- A higher concentration of IL-8 after probiotic supplementation, prior to infection, indicating priming of the immune system
*Based on an IQVIA ProVoice® survey of Primary Care Physicians who preferred HOWARU® B. lactis Bl-04® B. lactis Bl-04® for Respiratory Health after review of select clinical studies; December 2018. This claim cannot be used without a trade mark licensing agreement from IFF or its affiliates.
With over 70% of the immune system residing in the digestive tract, our gut is the first line of defense against potentially harmful pathogens and is closely related to overall health. This is why IFF offers a full range of immune health probiotic options for every stage of life.
